Oruka Therapeutics (ORKA) News Today $11.99 -0.37 (-2.99%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$11.91 -0.08 (-0.67%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by AnalystsShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have received an average recommendation of "Buy" from the nine research firms that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the compaMarch 12, 2025 | marketbeat.comWe're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn RateMarch 8, 2025 | finance.yahoo.comOruka Therapeutics' (ORKA) "Outperform" Rating Reaffirmed at WedbushWedbush reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Friday.March 8, 2025 | marketbeat.comOruka Therapeutics at Risk: Navigating Licensing Challenges and Partner RelianceMarch 8, 2025 | tipranks.comOruka Therapeutics announces preclinical data for ORKA-002March 7, 2025 | markets.businessinsider.comOruka Therapeutics (NASDAQ:ORKA) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPSOruka Therapeutics (NASDAQ:ORKA - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.19.March 7, 2025 | marketbeat.comOruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual MeetingMarch 7, 2025 | globenewswire.comOruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 6, 2025 | globenewswire.comOruka Therapeutics sees $1.41 million in stock purchases by Venrock HealthcareMarch 1, 2025 | investing.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires $106,396.06 in StockOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par acquired 8,971 shares of the business's stock in a transaction on Wednesday, February 12th. The stock was acquired at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the transaction, the insider now directly owns 4,044,684 shares in the company, valued at $47,969,952.24. The trade was a 0.22 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.February 28, 2025 | marketbeat.comInsider Buying: Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Acquires 88,794 Shares of StockOruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of Oruka Therapeutics stock in a transaction on Friday, February 14th. The stock was bought at an average price of $11.44 per share, with a total value of $1,015,803.36. Following the completion of the acquisition, the insider now directly owns 4,148,428 shares of the company's stock, valued at approximately $47,458,016.32. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.February 28, 2025 | marketbeat.comVenrock Healthcare Capital Par Purchases 8,971 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) StockFebruary 28, 2025 | insidertrades.comOruka Therapeutics (ORKA) to Release Earnings on ThursdayOruka Therapeutics (NASDAQ:ORKA) will be releasing earnings before the market opens on Thursday, February 27, Financial Modeling Prep reports.February 22, 2025 | marketbeat.comOruka Therapeutics to Present at Multiple March Investor ConferencesFebruary 19, 2025 | globenewswire.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have received a consensus rating of "Buy" from the nine brokerages that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating toFebruary 15, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)February 10, 2025 | markets.businessinsider.comOruka Therapeutics (NASDAQ:ORKA) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a report on Friday.February 7, 2025 | marketbeat.comWolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform RecommendationFebruary 6, 2025 | msn.comOruka Therapeutics inks exclusive license deal with ParagonFebruary 6, 2025 | msn.comWolfe Research Upgrades Oruka Therapeutics (NASDAQ:ORKA) to Strong-BuyWolfe Research upgraded Oruka Therapeutics to a "strong-buy" rating in a research note on Monday.February 5, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Time to Buy?Oruka Therapeutics (NASDAQ:ORKA) Shares Gap Up - Still a Buy?February 4, 2025 | marketbeat.comWolfe Research Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)Wolfe Research began coverage on shares of Oruka Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $20.00 price objective for the company.February 4, 2025 | marketbeat.comOruka Therapeutics initiated with an Outperform at Wolfe ResearchFebruary 3, 2025 | markets.businessinsider.comOruka Therapeutics (ORKA) Projected to Post Earnings on ThursdayOruka Therapeutics (NASDAQ:ORKA) will be releasing earnings before the market opens on Thursday, February 6, Financial Modeling Prep reports.January 30, 2025 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Buy" from AnalystsShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have been assigned an average recommendation of "Buy" from the eight ratings firms that are covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating onJanuary 21, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month Low - Here's What HappenedOruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month Low - Time to Sell?January 17, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Quotes, Forecast and News SummaryJanuary 16, 2025 | benzinga.comTop 3 Stocks to Watch This Week: PACS, Oruka, and Constellium NVJanuary 14, 2025 | theglobeandmail.comOruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8% - Should You Sell?Oruka Therapeutics (NASDAQ:ORKA) Trading Down 7.8% - Should You Sell?January 13, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Sets New 1-Year Low - What's Next?Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year Low - Time to Sell?January 10, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 8% - What's Next?Oruka Therapeutics (NASDAQ:ORKA) Shares Down 8% - Here's What HappenedJanuary 7, 2025 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month Low - Here's WhyOruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month Low - Here's WhyDecember 30, 2024 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of "Buy" from BrokeragesShares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have earned a consensus recommendation of "Buy" from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assignDecember 27, 2024 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Trading Down 3.2% - Time to Sell?Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.2% - Should You Sell?December 26, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)December 25, 2024 | markets.businessinsider.comOruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading Volume - Here's WhyOruka Therapeutics (NASDAQ:ORKA) Sees Strong Trading Volume - Here's What HappenedDecember 24, 2024 | marketbeat.comFranklin Resources Inc. Takes $17.66 Million Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Franklin Resources Inc. purchased a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 720,547 sDecember 21, 2024 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Celldex (CLDX), Oruka Therapeutics (ORKA) and Adicet Bio (ACET)December 20, 2024 | markets.businessinsider.comOruka Therapeutics’s ORKA-001: Promising Psoriasis Treatment Drives Buy Rating with 12-Month Price Target of $45December 20, 2024 | markets.businessinsider.comOruka Therapeutics doses first participants in Phase 1 trial of ORKA-001December 20, 2024 | finance.yahoo.comOruka Therapeutics (NASDAQ:ORKA) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of Oruka Therapeutics in a research report on Friday.December 20, 2024 | marketbeat.comOruka Therapeutics (NASDAQ:ORKA) Stock Price Down 4.7% - What's Next?Oruka Therapeutics (NASDAQ:ORKA) Trading Down 4.7% - Should You Sell?December 19, 2024 | marketbeat.comOruka Therapeutics, Inc.: Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)December 19, 2024 | finanznachrichten.deOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 AntibodyDecember 19, 2024 | globenewswire.comWellington Management Group LLP Acquires New Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)Wellington Management Group LLP bought a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 82,137 shares of the company'December 19, 2024 | marketbeat.comOruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)December 18, 2024 | globenewswire.comOruka Therapeutics (NASDAQ:ORKA) Sees Large Volume Increase - Should You Buy?Oruka Therapeutics (NASDAQ:ORKA) Sees Unusually-High Trading Volume - Here's What HappenedDecember 16, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 42,298 shares of the company'sDecember 13, 2024 | marketbeat.comOruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%December 11, 2024 | finance.yahoo.comOruka Therapeutics (ORKA) Gets a Buy from TD CowenDecember 11, 2024 | markets.businessinsider.com Remove Ads Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address ORKA Media Mentions By Week ORKA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORKA News Sentiment▼1.890.79▲Average Medical News Sentiment ORKA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORKA Articles This Week▼13▲ORKA Articles Average Week Remove Ads Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IRON News Today SDGR News Today GLPG News Today AAPG News Today MESO News Today IDYA News Today KNSA News Today WVE News Today IMCR News Today ANIP News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORKA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
